The research grant
Below, you will find all the relevant information you need to know in case you are interested in participating in the Type 2 Innovation Grant (the “Terms of Participation”). Your participation in the Type 2 Innovation Grant will be governed by these Terms of Participation. Sanofi Genzyme has the right to change the Terms of Participation at any time, for any reason, and without further notice. It is therefore recommended that you check these Terms of Participation on a regular basis.
1. What is the objective of the Type 2 Innovation Grant?
The objective of the Type 2 Innovation Grant is to support independent, novel and innovative research projects investigating Type 2 immune-mediated diseases, such as atopic dermatitis, asthma or chronic rhinosinusitis with nasal polyps (CRSwNP) (or “Type 2 immune-mediate diseases with relevance in clinical practices”).
Qualifying research grant applicants will be requested to select between two disease areas, Dermatology or Respiratory and, in this latter category, applicants must also choose if their proposal is related to Pulmonology or Rhinology. The applications will then be evaluated against predefined criteria by two independent panels of international experts, one per disease area.
The ten most relevant projects (5 in Dermatology and 5 in Respiratory – of which 4 will be related to pulmonary diseases and 1 will be related to rhinology) will be selected and each will receive a one-time research grant of up to EUR 80,000 (subject to the fulfillment of the conditions specified under point 8 below).
2. Which types of research projects are eligible for submission for a research grant application?
Your research projects must be designed to advance knowledge in the field of Type 2 immune-mediated diseases, including atopic dermatitis, asthma and chronic rhinosinusitis with nasal polyps, with relevance to clinical practice. Research projects with clear potential to advance patient care outcomes or reduce individual disease burden will be prioritized.
Research projects related to investigational or marketed medicinal product, and to diagnostic tests on humans are not accepted.
3. What qualifies as a Type 2 immune-mediated disease?
Your research projects must have a direct relevance to the mechanism of Type 2 immunity and should therefore include conditions such as atopic dermatitis, asthma and chronic rhinosinusitis with nasal polyps.
You will be requested to select between two disease areas when applying – Dermatology or Respiratory, in this latter case you must choose if your proposal is related to Pulmonology or Rhinology.
4. What is the amount of the research grant?
Sanofi Genzyme will financially support each winning research project with a research grant up to EUR 80,000 (subject to fulfillment of the conditions specified under point 8 below).
The exact amount of the research grant will be decided by Sanofi Genzyme taking into account the budget breakdown submitted by the applicant in support of the research grant application.
5. Who can submit a research grant application?
Only not-for-profit organizations can apply for a research grant. The institutions of our expert panel members are excluded from participation in the Type 2 Innovation Grant. See “The requirements” tab for more information.
6. How can you submit a research grant application?
Applications can only be submitted through this website. See “The application process” tab for more information.
7. What is the deadline for applications for a research grant?
You have until May 31st 2020 to submit your application. See “The application process” tab for more information. Costs in relation to the research grant application will be borne by the applicant.
8. Who will select the winning research projects?
All qualifying research grant applications will be evaluated by an independent panel of international experts (either by the Dermatology or by the Respiratory panel, depending on the selected disease area). Experts will select the five most relevant research projects submitted for their disease area against predefined criteria (the “winning research projects”). For more information, see “The selection” and “The expert panel” tabs. The decisions of the expert panel are final. There will be no further correspondence on the method of selection and the outcome of the selection process.
The applicants of the winning research projects will each receive a research grant, provided that the following cumulative conditions are met:
- Each applicant will have to go through, and successfully pass, a Sanofi Genzyme-led due diligence process
- Each applicant will have to enter into a research grant agreement with Sanofi Genzyme in accordance with applicable laws and regulations and Sanofi corporate policies and standards
Important: In cases where the above conditions are not met, the relevant applicant will not receive a research grant, in which case the research grant may be provided to another research project to be selected by the expert panel. The same applies in cases where applicable laws and regulations would prohibit Sanofi Genzyme from providing the research grant to the relevant applicant.
9. When will the winning research projects be announced?
Following completion of the expert panel selection process, the applicants of the winning research projects will be contacted by Sanofi Genzyme. This is expected to happen by September 2020. Public announcement of the winning research projects will take place following successful completion of the due diligence process referred to above in point 8.
10. When will the research grant be paid?
Sanofi Genzyme will pay the research grant within 30 days following the execution of the Research Grant Agreement referred to above in point 8.
11. How long is the research grant period?
The research grant period is 12 months from the moment of payment of the research grant.
12. What else do you need to know?
Intellectual property & publicity: Intellectual property rights in relation to a research project remain with the applicant who has submitted the research grant application. Sanofi Genzyme and IntraMed have a perpetual and worldwide right to use, store and give publicity to all submitted research grant applications and the (winning) research projects for purposes related to the Type 2 Innovation Grant. Such publicity may include publication on the internet and at conferences and seminars but is not limited thereto.
Expectations from winning applicants: The winning research project needs to be carried out within a period of 12 months (starting from the date of receipt of the research grant). In addition, an interim report will have to be provided to Sanofi Genzyme after 6 months and a final report after 12 months. Lastly, the applicant of a winning research project will have to publish the results of the research project in a peer-reviewed journal. Sanofi Genzyme might ask winning applicants to present on-going and final results of winning research projects during meetings and events (internal or external).
Data protection: Please read our Data Protection Notice that explains Sanofi Genzyme’s policies and practices regarding the processing of personal data that applicants provide in connection with their participation in the Type 2 Innovation Grant.
Limitation of liability: Sanofi Genzyme, IntraMed and the expert panel will not be liable for any damages of applicants resulting from participation in the Type 2 Innovation Grant.
Other: Sanofi Genzyme decides on all matters not covered by these Terms of Participation. Sanofi Genzyme may unilaterally terminate the Type 2 Innovation Grant at any time for any reason.
Governing law and disputes: These Terms of Participation and your participation in the Type 2 Innovation Grant are governed by Dutch law. Disputes in relation to the Type 2 Innovation Grant and/or these Terms of Participation shall be exclusively brought before the district court in Amsterdam, The Netherlands.